Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125224 | 0.87 | PARP1 (0.37) | PARP1HTR1A | |
| SCHEMBL4501824 | 0.70 | — | — | |
| SCHEMBL25376150 | 0.66 | CYP2B6 (0.30) | — | |
| SCHEMBL31635833 | 0.64 | PARP1 (0.34) | PARP1HTR1A | |
| Hydrochloric Acid SCHEMBL11632825 | 0.63 | PARP1 (0.33) | PARP1 | |
| SCHEMBL19305561 | 0.63 | PARP1 (0.50) | PARP1 | |
| SCHEMBL4892208 | 0.63 | PARP1 (0.40) | PARP1 | |
| SCHEMBL12021878 | 0.62 | HTR1A (0.40) | PARP1HTR1A | |
| SCHEMBL30439933 | 0.60 | ALDH1A1 (0.47) | PARP1 | |
| SCHEMBL30220270 | 0.60 | ALDH1A1 (0.47) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1640369-A1 | THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | CMA1, TH, NPR3 | PARP1 4360/4885HTR1A 889/4885 |
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | PARP1 1943/4885HTR1A 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.